Haleon plc stock (GB00BMX86B70): Consumer health giant navigates post-spin-off growth

Haleon plc, the consumer health spin-off from GSK, continues to focus on power brands like Sensodyne and Panadol amid evolving market dynamics for US investors.

Haleon plc operates as a leading consumer health company, offering products in oral care, pain relief, digestive health, and vitamins. The company, spun off from GlaxoSmithKline in 2022, maintains a strong presence in global markets with key brands driving revenue. US investors track Haleon for its exposure to stable consumer staples amid economic shifts.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Haleon plc
• Sector/industry: Consumer health / Personal care
• Headquarters/country: United Kingdom
• Core markets: North America, Europe, emerging markets
• Key revenue drivers: Oral care, upper respiratory, digestive health
• Home exchange/listing venue: London Stock Exchange (HLN.L)
• Trading currency: GBP

Haleon plc: core business model

Haleon plc focuses on consumer healthcare products sold directly to end-users through retail channels. The portfolio spans oral health (Sensodyne, Polident), pain relief (Panadol, Voltaren), and nutritional care (Centrum). This direct-to-consumer approach minimizes reliance on prescriptions, providing resilience in volatile markets. The model emphasizes innovation in established brands, with R&D centered on efficacy and consumer preferences, as outlined in the company's investor overview as of 2025.

Geographically, Haleon generates substantial revenue from North America, which accounts for a significant portion of sales due to strong brand penetration in the US. The company's structure post-GSK spin-off allows agile decision-making, with dedicated management focused on organic growth and bolt-on acquisitions in high-growth categories.

Main revenue and product drivers for Haleon plc

Oral care remains Haleon's largest segment, led by Sensodyne, the world's top toothpaste for sensitive teeth. Pain management products like Advil (in select markets) and Panadol contribute steadily, benefiting from consistent consumer demand. Digestive health brands such as Eno and Tums bolster the portfolio, particularly in the US where over-the-counter remedies see robust sales.

Vitamins and supplements, including Centrum, drive growth in the wellness category. Haleon reported North American revenue of £2.8 billion for the full year 2024 (published March 2025), representing about 35% of group turnover, highlighting US market importance for American investors tracking consumer health trends.

Industry trends and competitive position

The consumer health sector grows at 5-7% annually, fueled by aging populations and self-care trends, per IQVIA data as of 2025. Haleon competes with Procter & Gamble, Johnson & Johnson, and Reckitt, differentiating through science-backed power brands holding leading market shares in 70% of categories.

In the US, Haleon's brands like Thermacare and Flonase OTC position it well against private-label pressures. Sustainability initiatives, including recyclable packaging, align with ESG demands from US institutional investors.

Why Haleon plc matters for US investors

Haleon offers US investors exposure to defensive consumer staples with global scale but strong North American footprint. Listed on the LSE with ADRs available via OTC markets, it provides currency diversification while tapping US retail pharmacy channels. Economic resilience shown in past downturns appeals to portfolios seeking stability amid inflation concerns.

Conclusion

Haleon plc stands as a pure-play consumer health leader with powerhouse brands fueling steady revenue. Its US exposure and defensive qualities resonate with American investors seeking reliability. Market dynamics will continue shaping performance, warranting ongoing monitoring of category trends and execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.